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Utilizing tumors as a source of vaccination antigens in
immunotherapy has demonstrated promising results
with minimal toxicity. Unfortunately, researchers have
failed to overcome the overpowering suppressive effects
of the tumor microenvironment. Recently we demon-
strated that the proximity of the vaccination injection
site to the primary tumor site dictates CD8 T-cell priming
within the draining lymph node. Glioma-bearing mice vac-
cinated in tumor-distal sites had increased functional
responses and survived significantly longer than glioma-
bearing mice vaccinated in tumor-proximal sites due to
immunosuppressive properties of the tumor inhibiting the
priming of a tumoricidal response in the draining lymph
nodes. Tumor induced immunosuppression is a complex
interplay between the tumor and its surrounding microen-
vironment. We discovered an excess of soluble CD200
protein in the cerebral spinal fluid and cervical lymph
nodes in tumor bearing mice. CD200 has been well char-
acterized to be immunosuppressive in multiple graft rejec-
tion models, but has not been clearly defined as a factor in
tumor-induced suppression. CD200 is highly expressed
on a variety of human tumors including melanoma and
glioblastoma and is co-expressed on tumor stem cells.
CD200 is thought to be a mechanism by which these cells
escape immune surveillance. Researchers have shown that
specific peptide domains within the CD200 protein have
antagonist activity (act as competitive inhibitors for
CD200) for the CD200R. Together these data lead us to
the development of our central hypothesis that tumor-
induced immunosuppression is reversible using select
competitive inhibitors of CD200. We have synthesized
several competitive inhibitors by inoculating mice with
tumor lysate vaccines. Preliminary data show that these
inhibitor peptides derived from CD200 reverse immune
suppression within lymph nodes, significantly extending
survival of vaccinated glioma GL261-bearing and breast
carcinoma EMT6-bearing mice. Due to the homology
between human and mouse CD200, we further hypothe-
size that the use of CD200 inhibitors will be translatable
to human cancers. IMPACT: This study is designed to
elucidate and overcome the mechanism of tumor-induced
immunosuppression and has major implications for the
design of translational research approaches and future
clinical trials. If our hypothesis is correct, the use of a
competitive inhibitor may overcome the suppressive prop-
erties of the tumor in both the sentinel lymph nodes
as well within the tumor microenvironment, ultimately
leading to the development of novel therapeutics that
increase the efficacy of cancer immunotherapy.
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